| scholarly article | Q13442814 |
| P2093 | author name string | Kazuhiko Nakagawa | |
| Taroh Satoh | |||
| Masataka Katashima | |||
| Taiji Sawamoto | |||
| Tetsuya Nishimura | |||
| Yumiko Aoyama | |||
| P2860 | cites work | A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma | Q63874514 |
| Involvement of human organic cation transporter 1 in the hepatic uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel, small molecule survivin suppressan | Q84059609 | ||
| Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer | Q84420058 | ||
| When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective | Q84755383 | ||
| Evidence-based practice guideline for the treatment of CKD | Q84978295 | ||
| K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification | Q29547560 | ||
| Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. | Q36934286 | ||
| Emerging evidence of the impact of kidney disease on drug metabolism and transport | Q37128651 | ||
| YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model | Q39578508 | ||
| Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma | Q39607547 | ||
| Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models | Q39612451 | ||
| Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors | Q40388768 | ||
| YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. | Q51794884 | ||
| Tables | Q56385764 | ||
| P433 | issue | 3 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| sepantronium bromide | Q27268284 | ||
| P304 | page(s) | 373-380 | |
| P577 | publication date | 2012-07-18 | |
| P1433 | published in | Cancer Chemotherapy and Pharmacology | Q326137 |
| P1476 | title | Pharmacokinetics of sepantronium bromide (YM155), a small-molecule suppressor of survivin, in Japanese patients with advanced solid tumors: dose proportionality and influence of renal impairment | |
| P478 | volume | 70 |
| Q38115574 | Manipulating the apoptotic pathway: potential therapeutics for cancer patients |
| Q35049080 | Response of Merkel cell polyomavirus-positive merkel cell carcinoma xenografts to a survivin inhibitor |
| Q38750224 | Small Molecule Survivin Inhibitor YM155 Displays Potent Activity Against Human Osteosarcoma Cells |
| Q45191171 | The Effect of Uremic Solutes on the Organic Cation Transporter 2. |
| Q46889307 | YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation. |
Search more.